tetano
Editor, Senior Moderator
Stem Cell Res Ther
. 2020 May 27;11(1):207.
doi: 10.1186/s13287-020-01725-4.
Intravenous Infusion of Human Umbilical Cord Wharton's Jelly-Derived Mesenchymal Stem Cells as a Potential Treatment for Patients With COVID-19 Pneumonia
Yingxin Zhang[SUP] 1 [/SUP], Jie Ding[SUP] 1 [/SUP], Shaoda Ren[SUP] 1 [/SUP], Weihua Wang[SUP] 1 [/SUP], Yapei Yang[SUP] 1 [/SUP], Shuangjing Li[SUP] 1 [/SUP], Min Meng[SUP] 1 [/SUP], Tiejun Wu[SUP] 2 [/SUP], Daliang Liu[SUP] 3 [/SUP], Suochen Tian[SUP] 2 [/SUP], Hui Tian[SUP] 2 [/SUP], Shuangfeng Chen[SUP] 4 [/SUP], Changhui Zhou[SUP] 5 [/SUP]
Affiliations
Abstract
The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton's jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People's Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3[SUP]+[/SUP], CD4[SUP]+[/SUP], and CD8[SUP]+[/SUP] T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.
Keywords: COVID-19; Human umbilical cord Wharton’s jelly-derived MSCs; Immunomodulatory; Treatment.
. 2020 May 27;11(1):207.
doi: 10.1186/s13287-020-01725-4.
Intravenous Infusion of Human Umbilical Cord Wharton's Jelly-Derived Mesenchymal Stem Cells as a Potential Treatment for Patients With COVID-19 Pneumonia
Yingxin Zhang[SUP] 1 [/SUP], Jie Ding[SUP] 1 [/SUP], Shaoda Ren[SUP] 1 [/SUP], Weihua Wang[SUP] 1 [/SUP], Yapei Yang[SUP] 1 [/SUP], Shuangjing Li[SUP] 1 [/SUP], Min Meng[SUP] 1 [/SUP], Tiejun Wu[SUP] 2 [/SUP], Daliang Liu[SUP] 3 [/SUP], Suochen Tian[SUP] 2 [/SUP], Hui Tian[SUP] 2 [/SUP], Shuangfeng Chen[SUP] 4 [/SUP], Changhui Zhou[SUP] 5 [/SUP]
Affiliations
- PMID: 32460839
- DOI: 10.1186/s13287-020-01725-4
Abstract
The novel coronavirus disease 2019 (COVID-19) has grown to be a global public health emergency since patients were first detected in Wuhan, China. Thus far, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. The immune system and inflammation are proposed to play a central role in COVID-19 pathogenesis. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. Intravenous infusion of MSCs has shown promising results in COVID-19 treatment. Here, we report a case of a severe COVID-19 patient treated with human umbilical cord Wharton's jelly-derived MSCs (hWJCs) from a healthy donor in Liaocheng People's Hospital, China, from February 24, 2020. The pulmonary function and symptoms of the patient with COVID-19 pneumonia was significantly improved in 2 days after hWJC transplantation, and recovered and discharged in 7 days after treatment. After treatment, the percentage and counts of lymphocyte subsets (CD3[SUP]+[/SUP], CD4[SUP]+[/SUP], and CD8[SUP]+[/SUP] T cell) were increased, and the level of IL-6, TNF-α, and C-reactive protein is significantly decreased after hWJC treatment. Thus, the intravenous transplantation of hWJCs was safe and effective for the treatment of patients with COVID-19 pneumonia, especially for the patients in a critically severe condition. This report highlights the potential of hWJC infusions as an effective treatment for COVID-19 pneumonia.
Keywords: COVID-19; Human umbilical cord Wharton’s jelly-derived MSCs; Immunomodulatory; Treatment.